Vendor take-back financing in pharmacy sales

Picture this: You have found the perfect pharmacy. The location is ideal, the prescription volume is strong, the books are clean. You have been approved for bank financing, but there is a problem.

The bank will finance 75% of the $1,500,000 purchase price, which means $1,125,000. You have saved $225,000 for the down payment. But that still leaves you $150,000 short of what you need to close the deal.

This is where vendor take-back (VTB) financing can save the transaction.

Vendor take-back financing is when the seller provides a loan to the buyer for part of the purchase price. Instead of receiving full payment at closing, the seller agrees to be paid over time with interest, in our experience usually over 2 to 5 years. This arrangement bridges financing gaps, demonstrates seller confidence in the business, and often means the difference between a deal that closes and one that collapses.

In the Canadian pharmacy transactions we work on, VTB financing is common and often expected by buyers who cannot cover the entire purchase price with bank financing and personal equity. Understanding how VTB works, what terms are market-standard, and when it makes sense for both parties is essential for successful pharmacy sales.

Quick Summary: What You Will Learn

• What vendor take-back financing is and how it works in pharmacy transactions
• Typical VTB structures, amounts, and terms for Canadian pharmacy sales
• How to protect both buyers and sellers in VTB arrangements
• Tax implications for sellers providing vendor financing
• When VTB makes sense and when to avoid it
• Other creative financing structures beyond traditional VTB

What Is Vendor Take-Back Financing?

Vendor take-back financing (also called seller financing, vendor financing, or seller carry-back) occurs when the seller of a business acts as a lender by allowing the buyer to pay part of the purchase price over time rather than all at once at closing.

How VTB Works in Practice

Standard transaction structure without VTB:

Transaction structure with VTB:

The VTB amount becomes a loan from seller to buyer. It is usually secured by the business assets (in an asset sale) or the shares (in a share sale), but only if the parties agree to that security and it is properly registered. The buyer makes regular payments (monthly, quarterly, or annually) with interest until the loan is fully repaid.

Why Buyers Want Vendor Take-Back Financing

From the buyer’s perspective, VTB financing provides several advantages:

1. Bridges Financing Gaps

This is the most common reason buyers request VTB.

In our experience, Canadian banks often finance about 70% to 80% of a pharmacy purchase price for qualified buyers. If the buyer has saved enough for a 15% to 20% down payment but not the full 25% to 30% the bank requires, VTB fills the gap.

Example: A buyer has $225,000 saved. The pharmacy costs $1,500,000. The bank approves 75% financing ($1,125,000) but requires proof of the remaining 25% ($375,000). The buyer is $150,000 short. A 10% VTB ($150,000) can make the deal work without the buyer needing to find additional cash or outside investors, but only if the bank agrees to count the VTB toward its equity requirement. Many banks will only do that when the VTB is fully postponed (for example, no payments for a set period), so confirm the bank’s position in writing before you rely on it.

2. Reduces Required Cash Investment

Even buyers who have the full down payment sometimes prefer VTB to preserve cash for working capital, renovations, or personal financial security.

A buyer with $375,000 available might prefer to put down only $225,000 and keep $150,000 in reserve. The VTB provides that flexibility while still allowing the seller to receive the agreed purchase price.

3. Signals Seller Confidence

When sellers offer VTB, buyers interpret this as confidence in the business. If the seller is willing to take payments over time, it suggests they believe the pharmacy will continue generating sufficient cash flow to support those payments.

Conversely, sellers who refuse any VTB sometimes raise buyer concerns: Why won’t they take even a small portion over time? Do they know something about the business that makes them want all cash immediately?

4. May Reduce Bank Financing Requirements

Some banks view VTB as additional equity (or at least quasi-equity) that reduces their risk. A buyer with 15% cash down plus 10% VTB may receive more favourable bank loan terms than a buyer with only 15% down and no VTB. This is a lender decision, not a rule: an amortizing VTB that is paid monthly from day one does not automatically replace required cash equity.

Banks typically require that the VTB be fully subordinated to their loan, meaning the bank gets paid first if the pharmacy fails. The subordination agreement often goes further: it can block VTB payments while the bank loan is in default or a covenant is breached, limit prepayment, and stop the seller from enforcing its security without the bank’s consent.

Why Sellers Should Consider Providing VTB

Many sellers instinctively resist VTB. They want their money now, not payments over several years. However, VTB offers several benefits that sellers often overlook:

1. Expands the Buyer Pool

The more buyers who can afford your pharmacy, the more competition for it, and the better your negotiating position.

A seller who lists a pharmacy for sale on all-cash terms limits the buyer pool to only those with substantial liquid assets. Offering 10% to 15% VTB opens the sale of your pharmacy to qualified pharmacists who have bank approval and solid down payments but not quite enough for the full equity requirement.

Illustrative example, two scenarios for a $1,500,000 pharmacy for sale (the buyer counts and offers are assumptions to show the idea, not data):

Scenario A, seller requires all cash:

• Buyer needs $375,000 cash (25% down) plus bank approval for $1,125,000
• Buyer pool: 3 qualified buyers
• Best offer: $1,450,000 (buyer leverages limited competition)

Scenario B, seller offers 10% VTB:

• Buyer needs only $225,000 cash (15% down) plus bank approval
• Buyer pool: 8 qualified buyers
• Best offer: $1,500,000 (multiple competing buyers drive full price)

In Scenario B, the seller gets a higher headline price, but that does not automatically mean more value. $150,000 of it arrives over time and depends on the buyer paying, so compare the two offers after allowing for timing, interest and the risk of default before deciding which is better.

2. Earns Interest Income

In pharmacy deals we have seen in 2025 and 2026, VTB loans have usually carried interest rates of about 6% to 8% (sometimes higher for riskier deals). This provides sellers with a return on the deferred portion.

Example: A $150,000 VTB at 7% interest over 3 years generates approximately $16,700 in interest income for the seller (assuming monthly payments with amortization).

While this is taxable income, it still provides compensation for the delayed payment.

3. May Facilitate Tax Planning

For sellers with significant capital gains, receiving part of the price in later years may allow a capital gains reserve, which spreads the taxable gain over several years (see the tax section below). That can sometimes reduce overall tax.

Consult with your accountant about whether a reserve benefits your specific tax situation. This strategy works better in some structures (asset sales vs. share sales) and for some sellers (those near income thresholds) than others.

4. Can Close Deals That Otherwise Fail

Sometimes the difference between a successful sale and no sale at all is the seller’s willingness to provide a modest VTB.

Waiting months for another buyer who has more cash often results in a stale listing, declining business performance, and eventually an even lower sale price.

Typical VTB Structures for Canadian Pharmacy Sales

Every deal is unique. The ranges below are typical ranges from our experience in pharmacy transactions, not fixed market rules.

VTB Amount: Often 10% to 15% of Purchase Price

In the pharmacy deals we see, VTBs most often fall around 10% to 15% of the total purchase price, which matches general BDC guidance on vendor financing. Very small VTBs may not change much for the buyer, and larger ones put more of the seller’s money at risk and can point to a buyer who is short of equity. There is no single cutoff; assess the amount against the buyer’s equity, the bank’s terms and the pharmacy’s cash flow.

For a $1,500,000 pharmacy (illustrative ranges):

Interest Rate: Often 6% to 8%

In pharmacy deals we have seen in 2025 and 2026, VTB interest rates have usually been set around 6% to 8%, slightly higher than bank loan rates to compensate sellers for the additional risk of being a junior lender.

The interest rate should reflect:

• Current market interest rates (the prime rate as a baseline)
• Risk level of the pharmacy (stronger businesses justify lower rates)
• The buyer’s financial strength (higher net worth buyers may negotiate lower rates)
• Whether the VTB is secured or unsecured

Rates move with the market, so treat the 6% to 8% range as a dated example. Set the actual rate by checking the current prime rate and bank pricing at the time of your deal, then adjusting for the factors above.

Term Length: Often 2 to 5 Years

In our experience, VTB loans are usually structured with 2 to 5 year terms, with 3 years being common.

Shorter terms (2 years) reduce seller risk but create higher monthly payments for buyers. Longer terms (5 years) reduce the buyer’s payment burden but extend seller exposure.

Payment example for a $150,000 VTB at 7% interest:

The buyer’s pharmacy must generate sufficient cash flow to cover these VTB payments in addition to the bank loan payments and operating expenses.

Payment Schedule: Monthly Payments Most Common

Most VTB arrangements require monthly payments (principal plus interest) similar to a bank loan. This provides sellers with regular income and ensures the loan amortizes steadily. Whatever schedule you agree, the senior lender must approve it, and its subordination terms can pause or limit VTB payments, so get the bank’s sign off before promising a schedule to the seller.

Alternative payment structures include:

• Interest-only payments with a balloon: The buyer pays only interest monthly (7% of $150,000 = $875 per month) with the full $150,000 principal due at the end of the term. This reduces the buyer’s monthly payments but requires them to refinance or save for the balloon payment.
• Quarterly or annual payments: Larger, less frequent payments that align with business cash flow patterns. Works better for seasonal pharmacies.
• Deferred payments: No payments for the first 6 to 12 months to give the buyer time to stabilize the business, then regular payments begin.

Protecting Both Parties in VTB Arrangements

VTB financing creates risk for both buyers and sellers. Proper documentation and security provisions protect everyone. Each protection below is a negotiated term, not an automatic right: what it is worth depends on the contract wording, other creditors (especially the bank), and the law of your province, so have a lawyer in that province draft and register the documents.

Essential VTB Documentation

Promissory note: The legal document evidencing the loan. It specifies the principal amount, interest rate, payment schedule, term, and consequences of default.

Security agreement: In asset sales, the seller takes security (collateral) in the pharmacy assets purchased. In share sales, the seller may take security in the shares themselves or a general security agreement over the corporation’s assets.

Personal guarantee: The buyer personally guarantees the VTB debt, making them personally liable if the business cannot repay. Sellers commonly ask for this, and it helps protect them from buyers simply walking away, but it has to be negotiated and is only as good as the buyer’s personal finances.

Subordination agreement: If the buyer has bank financing, the bank will require that the VTB be subordinated (junior) to their loan. This means if the business fails, the bank gets paid first from liquidation proceeds, and the VTB holder only gets paid after the bank is fully satisfied. It usually also covers what happens before any failure: the bank can require a payment standstill (no VTB payments while the bank loan is in default or a covenant is breached), limit or block prepayment of the VTB, and restrict the seller from accelerating or enforcing without the bank’s consent. Read it carefully before you sign the VTB terms.

Protections for Sellers

• Security in business assets: Register your security interest in the pharmacy’s assets (equipment, fixtures, inventory, accounts receivable) through the Personal Property Security Act (PPSA) registry in your province. In Quebec, the equivalent is a movable hypothec under the Civil Code, published in the Register of Personal and Movable Real Rights. Properly registered security generally ranks ahead of unsecured creditors if the buyer defaults, but your actual priority depends on registration timing, the bank’s security and the subordination agreement, so have your lawyer run searches and confirm perfection.
• Acceleration clause: If the buyer misses payments or breaches terms, the contract can make the entire remaining balance immediately due. This helps stop buyers from dragging out defaults for months, although the bank’s subordination terms may limit when you can use it.
• Right to financial information: Include provisions requiring the buyer to provide quarterly or annual financial statements so you can monitor business performance and identify problems early.
• Notice and cure periods: Require written notice if the buyer intends to make major business changes (sell the business, merge with another pharmacy, take on additional debt). Give yourself 30 to 60 days to respond or demand accelerated payment.
• Prepayment rights: Allow (but do not require) the buyer to prepay the VTB early without penalty, subject to the bank’s consent where the subordination agreement requires it. Include a term that the VTB is paid out if the buyer sells the pharmacy, and expect the bank to have its own say in a refinancing.

Protections for Buyers

• Partial release provisions: If you make significant prepayments or pay down a certain percentage, the seller releases some collateral. This gives you more financial flexibility as you pay down the debt.
• Reasonable interest rate: Check the VTB interest rate against current bank pricing and the deal’s risk and security (in deals we have seen in 2025 and 2026, about 6% to 8% has been usual). A noticeably higher rate is worth questioning, but it can be fair if the risk is higher or the security is weak.
• Clear payment terms: Specify exact payment amounts, due dates, and acceptable payment methods. Ambiguity creates disputes.
• Limited negative covenants: Some sellers try to restrict what you can do with the business (no expansion, no additional borrowing, no changes to suppliers). Negotiate reasonable limits that give you operational flexibility while protecting the seller’s security.

Tax Implications of Vendor Take-Back Financing

VTB financing creates tax consequences for both parties. This section is general information, not tax advice; the right answer depends on who the buyer and seller are (individual, holding company or operating company), so have your accountant model your own deal.

For Sellers: Capital Gains vs. Interest Income

When you provide VTB, the full capital gain is still calculated in the year of sale (assuming an asset or share sale structure with capital treatment). How much of that gain you must report in that year is a separate question.

Example: You sell your pharmacy for $1,500,000 in a share sale. Your adjusted cost base (what you paid for the shares years ago) was $300,000. Your capital gain is $1,200,000.

Capital gains reserve. Because $150,000 of the price is paid later through the VTB, you may be able to claim a capital gains reserve and bring part of the gain into income in later years as the money arrives. The reserve can generally spread the gain over up to five years (at least one fifth of the gain must be reported cumulatively each year), or up to ten years for qualified small business corporation shares transferred to your child. You claim it on Form T2017, and you recalculate it each year based on what is still unpaid. Whether you qualify depends on the facts of your sale, so confirm it with your accountant.

Illustration (simplified, assuming the full $150,000 is still owed at the end of the year of sale): the most you could reserve is about $1,200,000 × ($150,000 ÷ $1,500,000) = $120,000, so you would report about $1,080,000 of the gain in the year of sale and the remaining $120,000 in later years as the VTB is repaid.

The Lifetime Capital Gains Exemption ($1,275,000 in 2026 for qualified small business corporation shares) may shelter this entire gain from regular tax if your shares qualify and you have not used the exemption before. If it does, a reserve may add little. Alternative minimum tax can still apply, so ask your accountant to run both.

The interest you receive on the VTB is fully taxable. This is different from capital gains (50% inclusion rate): interest is 100% included in income and taxed at your marginal rate. When you report it depends on whether you hold the note personally or through a corporation and on the accrual rules that apply to the debt, so do not assume it is only taxed when the cash arrives.

Example: Your $150,000 VTB at 7% (amortized monthly over 3 years) generates about $9,025 in interest in the first 12 months. That amount is added to your other income and taxed at your marginal rate (potentially 45% to 50% in high-income provinces).

For Buyers: Interest Deductibility

Interest on a VTB is deductible by the party that borrowed, where the borrowed money was used to earn business or property income. It is not automatically a deduction for the pharmacy. Who gets the deduction depends on the structure:

• Asset purchase by the operating company: if the operating company buys the assets and owes the VTB, the interest is generally deductible by that company as a cost of earning its business income.
• Share purchase by a holding company: the holding company owes the VTB, so the interest expense sits in the holding company, not in the pharmacy. The holding company may have little income to deduct it against unless your accountant plans for that (for example, through an amalgamation after closing).
• Share purchase by you personally: the interest may be deductible on your personal return if the shares were bought to earn income, subject to the CRA’s interest deductibility rules.

Example (assuming the operating company is the borrower): The company pays about $9,025 in VTB interest in the first 12 months. At an assumed combined small business tax rate of 12%, that deduction saves about $1,083 in corporate tax ($9,025 × 12%). Your actual saving depends on your province, whether the income qualifies for the small business deduction, and the borrower.

The principal payments on the VTB are not tax-deductible. They are repayment of the purchase price, which was a capital transaction.

Allocation in Asset Sales

In asset sales, the purchase price must be allocated among different asset classes (inventory, equipment, goodwill, and so on). The CRA expects a reasonable allocation, and the parties usually agree it in the purchase agreement. This allocation affects both parties’ taxes; the CRA’s capital gains guidance explains how gains on each class are treated.

There is no fixed rule that the VTB must be spread across asset classes in proportion to the price allocation. How the deferred part of the price relates to each asset, and whether any reserve is available, should be set by your lawyer and accountant. The example below shows one simple approach, a proportionate split, for illustration only.

Illustrative example:

• Total purchase price: $1,500,000
• Allocation: Inventory $300,000 (20%), Equipment $150,000 (10%), Goodwill $1,050,000 (70%)
• VTB amount: $150,000 (10% of total)

Proportionate VTB split (one possible approach):

When VTB Makes Sense and When to Avoid It

VTB Makes Sense When:

The buyer is well-qualified but slightly short on cash. A licensed pharmacist with bank approval, solid management experience, and a reasonable down payment (15% to 20%) who needs a modest VTB (10% to 15%) to bridge the gap.

The pharmacy has strong, stable cash flow. The business generates enough cash flow to comfortably cover both bank debt service and VTB payments. Look for a debt service coverage ratio (DSCR), measured on all debt, that sits comfortably above the bank’s minimum covenant rather than just at it.

Market conditions favour buyers. If buyers are scarce and you need to make your deal more attractive, offering VTB differentiates you from sellers who demand all cash.

You can afford the risk. You do not desperately need all the cash at closing. You have other income sources or assets. You can afford to wait 2 to 5 years for full payment and can absorb the loss if the buyer defaults.

You want to facilitate a smooth transition. VTB aligns seller and buyer interests. If you hold a note, you have a vested interest in the pharmacy’s success and may be more motivated to support the buyer during transition.

Avoid VTB When:

The buyer has weak financials or limited experience. First-time buyers with minimal savings, no management experience, and marginal credit should not be financed through VTB. The risk of default is too high.

The pharmacy has declining performance. If prescription volume is falling, margins are compressing, or competition is intensifying, VTB magnifies your risk. You may be lending money to a failing business.

You need all the cash immediately. If you have debts to pay off, immediate retirement expenses, or other financial commitments that require full payment at closing, VTB is not appropriate.

The buyer requests a large VTB with little of their own cash. If most of the money the bank sees as “equity” is really your loan, the buyer may be under-capitalized. Some banks will decline the deal or ask for more cash, and you should look hard at the risk too. Assess the whole package (cash equity, bank terms, cash flow and security) rather than one percentage.

The transaction is already complex or contentious. If you and the buyer have had difficult negotiations, trust issues, or significant disputes during due diligence, VTB creates an ongoing relationship that may lead to further conflict.

Other Creative Financing Structures Beyond Traditional VTB

VTB is not the only creative financing option. Here are other structures used in pharmacy transactions:

Earnouts (Performance-Based Payments)

Instead of (or in addition to) VTB, the seller receives additional payments if the pharmacy achieves specific performance targets post-closing.

Structure:

• Base purchase price: $1,350,000 paid at closing
• Earnout: Up to $150,000 additional if the pharmacy maintains average monthly prescription volume above 5,000 scripts for each of the next 2 years

Earnouts align interests: the seller is incentivized to support a smooth transition, and the buyer only pays the full price if performance continues.

Risks: Disputes often arise about whether targets were met, whether the buyer operated the pharmacy properly, and whether declining performance was due to market factors or buyer mismanagement.

Consulting or Employment Agreements

Separately from the purchase price, the seller may stay on after closing as a paid consultant or employee to support the transition.

This is not a substitute for VTB and must not be used to relabel part of the purchase price. Payments under a consulting or employment agreement should be for real services actually provided after closing, at a fee that a third party would pay for that work. Those payments are taxed as income to the seller (employment income or business income, depending on the relationship), not as capital gains. Under the Income Tax Act, the CRA can look past the label and treat amounts according to what they are really paid for, so the characterization has to match the substance. Have a tax advisor review any post closing services agreement alongside the purchase agreement.

Real Estate Leaseback

If the seller owns the building where the pharmacy operates, they can sell the pharmacy business but retain the real estate and lease it to the buyer.

Structure:

• Pharmacy business sale: $1,500,000 (buyer pays $1,350,000 at closing, $150,000 VTB)
• Real estate: Seller retains ownership and leases to the buyer at $8,000 per month

This provides the seller with ongoing rental income (often more stable than VTB payments, though not guaranteed) and retains a valuable real estate asset that can be sold later or held long term.

Phased Buyout (Partnership Transition)

Instead of an immediate full sale, the buyer purchases an initial stake (30% to 50%) and buys the remainder over 3 to 5 years based on a predetermined formula.

Structure:

• Year 1: Buyer purchases 40% for $600,000 (based on a $1,500,000 valuation)
• Years 2 to 4: Buyer purchases an additional 20% each year at valuations based on trailing 12 month EBITDA

This can spread the seller’s tax liability over several years (depending on the structure and tax advice), maintains their involvement during transition, and allows the buyer to prove themselves before committing to the full purchase.

Worked Example: VTB Bridging a Financing Gap

This is an illustrative scenario based on the kind of deals we see. The names, figures, lender terms and outcome are assumptions for teaching, not a specific client file.

Scenario:

Sarah is selling her community pharmacy in suburban Calgary. The business generates $300,000 in normalized EBITDA. That figure is already after a market salary for the full time pharmacist manager role, which the buyer will fill and draw himself. Based on a 5x EBITDA multiple, the asking price is $1,500,000.

David is a licensed pharmacist working as an associate manager at another pharmacy. He has saved $225,000 for a down payment and has been pre-approved by a major Canadian bank for pharmacy acquisition financing.

The problem:

The bank will finance 75% of the purchase price ($1,125,000) but requires David to bring the remaining 25% ($375,000). David is $150,000 short. The bank also sets a minimum debt service coverage ratio (DSCR) of 1.25x, measured on all debt including any VTB. (Both conditions are assumptions for this example; lenders set their own terms.)

David considers several options:

• Wait another 2 years to save the additional $150,000. By then, Sarah’s pharmacy may be sold, market conditions may change, or the opportunity may be lost.
• Find an investor partner. Bring in a partner who contributes $150,000 for a 10% ownership stake. This dilutes David’s ownership and creates governance complexity.
• Request vendor take-back financing. Ask Sarah to provide a $150,000 VTB over 3 years at 7% interest.

The negotiation:

David explains his situation to Sarah and proposes:

• Purchase price: $1,500,000 (asset sale structure)
• Bank loan: $1,125,000 at 6.5% over 10 years
• David’s equity: $225,000 at closing
• VTB from Sarah: $150,000 at 7% interest over 3 years, monthly payments

Sarah is initially reluctant. She planned to use the full sale proceeds to pay off her mortgage and fund her retirement. However, her broker points out several benefits:

• David is well-qualified (licensed pharmacist, 7 years of management experience, good credit)
• The pharmacy has stable cash flow, which the bank will test against its coverage requirement
• Rejecting VTB may mean losing this buyer and waiting months for another
• The 7% interest rate provides a return on the deferred amount
• She can still access most of her equity immediately ($1,350,000 at closing)

The solution:

Sarah agrees to the VTB with the following protections:

• Security interest in the pharmacy assets (registered through PPSA)
• Personal guarantee from David
• Subordination agreement (the VTB is junior to the bank’s loan; in this example the bank agrees to count it toward David’s equity on its subordination terms)
• Quarterly financial reporting requirement
• Prepayment allowed without penalty, subject to the bank’s consent

The numbers:

First, the earnings measure. In this example the bank uses cash available for debt service: normalized EBITDA, less maintenance capital spending and estimated cash income taxes. David’s market salary is already deducted inside the $300,000 normalized EBITDA, so it is not subtracted a second time.

David’s obligations under the first proposal:

• Bank loan ($1,125,000 at 6.5% over 10 years): $12,774 per month ($153,290 per year)
• VTB to Sarah ($150,000 at 7% over 3 years): $4,632 per month ($55,579 per year)
• Total debt service: $17,406 per month ($208,869 per year)

DSCR = $250,000 / $208,869 = 1.20x

This is below the bank’s 1.25x minimum. To reach 1.25x with this much debt, cash available would need to be about $261,086 ($208,869 × 1.25), roughly $11,000 more than the pharmacy produces. Cutting David’s salary below market is not a real fix: the normalized figure assumes he is paid a fair wage for the job, and the bank knows it. The realistic fixes are structural: lower the total debt service through a lower price, more cash equity, or a longer VTB term. A plan to grow earnings helps the story, but banks usually lend on historical cash flow, not projections.

The revision:

After seeing the coverage issue, Sarah and David restructure:

• Sarah reduces the price slightly to $1,475,000 (recognizing the tight cash flow)
• David increases his cash equity to $250,000
• The bank finances $1,100,000
• VTB: $125,000 at 7% over 3 years

Check: $1,100,000 + $250,000 + $125,000 = $1,475,000.

New obligations:

• Bank loan ($1,100,000 at 6.5% over 10 years): $12,490 per month ($149,883 per year)
• VTB ($125,000 at 7% over 3 years): $3,860 per month ($46,316 per year)
• Total: $16,350 per month ($196,199 per year)

DSCR = $250,000 / $196,199 = 1.27x

This meets the 1.25x minimum, but only just. Cash available could fall by only about $4,750 ($250,000 minus $245,249, which is $196,199 × 1.25) before the ratio drops below 1.25x. For simplicity the tax estimate is held at $35,000; the slightly lower interest in the revised structure would raise taxes a little, which still leaves the ratio at about 1.27x.

Another option the bank might accept: keep the $1,500,000 price and stretch the $150,000 VTB to 5 years ($2,970 per month, $35,642 per year). Total debt service would be $153,290 + $35,642 = $188,932 per year, and DSCR = $250,000 / $188,932 = 1.32x. Sarah would get her full price but wait longer for the last of her money.

They choose the revised price. David also shows the bank a plan to grow earnings over the first 12 months through:

• Adding minor ailment prescribing services (Alberta allows this)
• Increasing medication review billing
• Reducing staff overtime through better scheduling

The bank treats that plan as upside, not as part of the coverage test. It approves based on:

• A DSCR that meets its covenant on historical, normalized cash flow
• David’s credentials and experience
• The pharmacy’s historical stability
• Sarah’s subordinated VTB, which also shows her confidence in the business

The outcome:

The deal closes. If David pays the VTB on schedule, Sarah receives:

• $1,350,000 at closing ($1,100,000 from the bank, $250,000 from David)
• $125,000 over 36 months plus about $13,947 in interest
• Total: about $1,488,947 over 3 years

If cash flow improves and the bank consents to an early payoff, prepayment changes the numbers. For example, if David pays off the VTB after 18 months, he will have paid about $10,242 in interest by then and pays the remaining principal of about $65,769 in one lump sum. Interest stops at the payoff date, so Sarah’s total becomes about $1,485,242 ($1,350,000 + $125,000 + $10,242) instead of about $1,488,947.

In this example, the VTB made the transaction possible. Without it, David could not have bought the pharmacy on these terms, and Sarah would have had to wait for another buyer or consider other offers.

Conclusion: VTB as a Transaction Tool

Vendor take-back financing is neither universally good nor bad. It is a tool that, when used appropriately, facilitates transactions that benefit both parties.

For buyers, VTB bridges financing gaps, reduces required cash investment, and signals seller confidence in the business. For sellers, VTB expands the buyer pool, earns interest income, and can close deals that would otherwise collapse.

The key is proper structuring and documentation. VTB arrangements must be secured, clearly documented, and reasonable in amount and terms. Both parties should consult lawyers and accountants before finalizing VTB terms.

When evaluating whether to offer or accept VTB, consider:

• The buyer’s qualifications and financial strength
• The pharmacy’s cash flow stability and growth trajectory
• Whether the VTB amount is reasonable for this deal (often 10% to 15% of the purchase price in our experience)
• Whether the interest rate compensates for risk (about 6% to 8% in deals we have seen in 2025 and 2026; check current rates)
• Whether the term is manageable (often 2 to 5 years)
• Whether the deal still meets the bank’s coverage requirement with the VTB payments included
• Whether proper security and documentation protect both parties

Used thoughtfully, VTB financing can turn difficult transactions into successful ones. It demonstrates flexibility, builds trust, and creates outcomes where both parties achieve their goals.

If you are buying or selling a pharmacy and exploring VTB options, our team provides expert guidance on structuring fair, secure, and market-competitive vendor financing arrangements. Contact us for a confidential consultation.